The Maintrac CTC Count Test
The Maintrac Circulating Stem Cell Count Test, can measure a patient’s cancer stem cells that have escaped into blood, by a simple blood test. A CTC Count test finds existing cancer cells (CTCs), and distinguishes live cancer cells from fragmented tumour cells and then analysed. CTC-count is an independent prognostic indicator, that is, it gives an indication of the aggressiveness of a patient’s cancer at the time of the test. The initial CTC count gives a valuable baseline indication of a patient’s current cancer status, and then subsequent tests help to monitor a patient’s response to treatment, as well as monitor long-term health.
Monitoring changes in cancer activity over time is made easy with this test
A CTC Count every 3-6 months is the best way to:
- Monitor the effectiveness of cancer treatment
- Assess changes in cancer aggressiveness
- Determine risk of cancer spread, recurrence or relapse
Maintrac® is a state-of-the-art German technology that detects, characterises and tests CTCs. It has been critically validated and published in peer reviewed journals for over 12 years. Maintrac® CTC tests are acknowledged and utilised by many universities, Oncologists and cancer clinics worldwide.